Back to top

The Zacks Analyst Blog Highlights: NextEra, Danaher, Biogen, Facebook and Apple

Read MoreHide Full Article

For Immediate Release

Chicago, IL – April 12, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include NextEra (NEE - Free Report) , Danaher (DHR - Free Report) , Biogen (BIIB - Free Report) , Facebook (FB - Free Report) and Apple (AAPL - Free Report) .

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for NextEra, Danaher and Biogen

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NextEra, Danaher and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Buy-ranked NextEra’s shares have outperformed the Zacks Electric Power industry over the last year (the stock is up +23.9% vs. -3.3% decline for the industry). NextEra Energy’s investment to strengthen its infrastructure and ongoing capital projects, when completed, will help it serve its expanding customer base more efficiently.

The Zacks analyst likes the company’s focus on clean energy, which has helped it lower emission levels and its use of new technology, which has saved on energy bills for its customers. The natural gas pipelines, which came online in first half of 2017, are expected to boost its performance.

However, the company’s nature of business is subject to complex and comprehensive federal, state and other regulations. Despite investments made to strengthen its infrastructure the unpredictable nature of natural disaster could derail normal operation and impact profitability.

Shares of Buy-ranked Danaher have gained +14.4% over the past six months, outperforming the Zacks Diversified Operations industry, which has declined -11.9% over the same period. Danaher has an excellent earnings history over the trailing four quarters, beating estimates all through.

The Zacks analyst is optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and rising healthcare spending. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues.

This apart, the company’s continuous introduction of products enables it to penetrate new markets and gain competitive edge in existing ones. However, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business might restrict growth, going forward. Moreover, weakness in industrial markets and stiff competition may also hurt the company's financials.

Biogen’s shares have underperformed the Zacks Biomedical and Genetics industry over the last three months (-21% vs. -9.8%). Biogen has a strong position in the MS market. The Zacks analyst also likes Biogen’s efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke, among others.

Meanwhile, its newest drug Spinraza witnessed strong patient uptake in the U.S. and internationally. However, weakening MS trends is a concern. Tecfidera is witnessing a slight decline in U.S. patient demand due to increasing competition from oral medicines and a slowdown in the overall MS market.

The launch of Ocrevus by Roche is beginning to have a negative impact on MS franchise sales in the U.S., mainly on Tysabri. Also, recently, Biogen announced the decision to withdraw Zinbryta from the markets due to growing safety concerns. However, estimates have risen ahead of Q1 earnings results. The company has a positive record of earnings surprises in recent quarters.

Other noteworthy reports we are featuring today include Facebook and Apple.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

http://www.zacks.com                                                   

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like